SSY Group Limited — Regulatory Filings 2021

Oct 11, 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [332 x 171] intentionally omitted <==

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has obtained the approval for drug production and registration for Lacosamide Tablets (50mg and 100mg) from the National Medical Products Administration of China, being under type 4 chemical new drug and regarded as passing the consistency evaluation. Lacosamide can regulate the activity of sodium ion channels, reduce the inward flow of sodium ions effectively and lower the excitability of neurons, so as to achieve the purpose of treating epilepsy. It is mainly used as monotherapy and combination therapy for partial-onset seizures in patients with epilepsy aged 4 years or above.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board Chow Hing Yeung Executive Director and Company Secretary

Hong Kong, 11 October 2021

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.